Literature DB >> 33380422

Cell autonomous angiotensin II signaling controls the pleiotropic functions of oncogenic K-Ras.

Daniela Volonte1, Morgan Sedorovitz1, Victoria E Cespedes1, Maria L Beecher1, Ferruccio Galbiati2.   

Abstract

Oncogenic K-Ras (K-RasG12V) promotes senescence in normal cells but fuels transformation of cancer cells after the senescence barrier is bypassed. The mechanisms regulating this pleiotropic function of K-Ras remain to be fully established and bear high pathological significance. We find that K-RasG12V activates the angiotensinogen (AGT) gene promoter and promotes AGT protein expression in a Kruppel-like factor 6-dependent manner in normal cells. We show that AGT is then converted to angiotensin II (Ang II) in a cell-autonomous manner by cellular proteases. We show that blockade of the Ang II receptor type 1 (AT1-R) in normal cells inhibits oncogene-induced senescence. We provide evidence that the oncogenic K-Ras-induced synthesis of Ang II and AT1-R activation promote senescence through caveolin-1-dependent and nicotinamide adenine dinucleotide phosphate oxidase 2-mediated oxidative stress. Interestingly, we find that expression of AGT remains elevated in lung cancer cells but in a Kruppel-like factor 6-independent and high-mobility group AT-hook 1-dependent manner. We show that Ang II-mediated activation of the AT1-R promotes cell proliferation and anchorage-independent growth of lung cancer cells through a STAT3-dependent pathway. Finally, we find that expression of AGT is elevated in lung tumors of K-RasLA2-G12D mice, a mouse model of lung cancer, and human lung cancer. Treatment with the AT1-R antagonist losartan inhibits lung tumor formation in K-RasLA2-G12D mice. Together, our data provide evidence of the existence of a novel cell-autonomous and pleiotropic Ang II-dependent signaling pathway through which oncogenic K-Ras promotes oncogene-induced senescence in normal cells while fueling transformation in cancer cells.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ras; angiotensin; caveolin; oncogene; senescence

Year:  2021        PMID: 33380422      PMCID: PMC7948762          DOI: 10.1074/jbc.RA120.015188

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  67 in total

1.  Somatic activation of the K-ras oncogene causes early onset lung cancer in mice.

Authors:  L Johnson; K Mercer; D Greenbaum; R T Bronson; D Crowley; D A Tuveson; T Jacks
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

2.  Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress.

Authors:  Alice T Shaw; Monte M Winslow; Margaret Magendantz; Chensi Ouyang; James Dowdle; Aravind Subramanian; Timothy A Lewis; Rebecca L Maglathin; Nicola Tolliday; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-09       Impact factor: 11.205

3.  Subcytotoxic H2O2 stress triggers a release of transforming growth factor-beta 1, which induces biomarkers of cellular senescence of human diploid fibroblasts.

Authors:  C Frippiat; Q M Chen; S Zdanov; J P Magalhaes; J Remacle; O Toussaint
Journal:  J Biol Chem       Date:  2000-11-01       Impact factor: 5.157

4.  Tumour biology: senescence in premalignant tumours.

Authors:  Manuel Collado; Jesús Gil; Alejo Efeyan; Carmen Guerra; Alberto J Schuhmacher; Marta Barradas; Alberto Benguría; Angel Zaballos; Juana M Flores; Mariano Barbacid; David Beach; Manuel Serrano
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

5.  Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo.

Authors:  Xiaopeng Li; Huiying Zhang; Valerie Soledad-Conrad; Jiaju Zhuang; Bruce D Uhal
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2002-11-15       Impact factor: 5.464

6.  Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.

Authors:  Stefan Wilop; Sabine von Hobe; Martina Crysandt; Albert Esser; Rainhardt Osieka; Edgar Jost
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-28       Impact factor: 4.553

7.  Inhibition of thioredoxin reductase 1 by caveolin 1 promotes stress-induced premature senescence.

Authors:  Daniela Volonte; Ferruccio Galbiati
Journal:  EMBO Rep       Date:  2009-10-09       Impact factor: 8.807

8.  Attenuation of bleomycin-induced pulmonary fibrosis by intratracheal administration of antisense oligonucleotides against angiotensinogen mRNA.

Authors:  Xiaopeng Li; Jiaju Zhuang; Heather Rayford; Huiying Zhang; Ruijie Shu; Bruce D Uhal
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

9.  Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence.

Authors:  Graeme Hewitt; Diana Jurk; Francisco D M Marques; Clara Correia-Melo; Timothy Hardy; Agata Gackowska; Rhys Anderson; Morgan Taschuk; Jelena Mann; João F Passos
Journal:  Nat Commun       Date:  2012-02-28       Impact factor: 14.919

10.  Cellular senescence mediates fibrotic pulmonary disease.

Authors:  Marissa J Schafer; Thomas A White; Koji Iijima; Andrew J Haak; Giovanni Ligresti; Elizabeth J Atkinson; Ann L Oberg; Jodie Birch; Hanna Salmonowicz; Yi Zhu; Daniel L Mazula; Robert W Brooks; Heike Fuhrmann-Stroissnigg; Tamar Pirtskhalava; Y S Prakash; Tamara Tchkonia; Paul D Robbins; Marie Christine Aubry; João F Passos; James L Kirkland; Daniel J Tschumperlin; Hirohito Kita; Nathan K LeBrasseur
Journal:  Nat Commun       Date:  2017-02-23       Impact factor: 14.919

View more
  1 in total

1.  Synergy of epidermal growth factor (EGFR) and angiotensin II (AT1R) receptor determines composition and temporal pattern of transcriptome variation.

Authors:  Barbara Schreier; Virginie Dubourg; Stefanie Hübschmann; Sindy Rabe; Sigrid Mildenberger; Michael Gekle
Journal:  Cell Mol Life Sci       Date:  2021-12-18       Impact factor: 9.261

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.